Shenzhen Hepalink Pharmaceutical

Hepalink to acquire Cytovance

Wednesday, August 26, 2015

Hepalink USA, a China-based global supplier of heparin sodium API, has entered into a definitive agreement to acquire Cytovance Biologics, a biopharmaceutical contract development manufacturing (CDMO) company, for $205.68 million in cash plus certain contingent payments.

[Read More]